Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aprea Therapeutics, Inc. - Common Stock
(NQ:
APRE
)
0.8642
-0.0358 (-3.98%)
Streaming Delayed Price
Updated: 3:06 PM EDT, May 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Aprea Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher
↗
Today 7:20 EDT
Via
Chartmill
Gapping stocks in Monday's session
↗
March 16, 2026
Via
Chartmill
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial
↗
February 18, 2026
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.
Via
Stocktwits
The market is filled with gapping stocks in Wednesday's session.
↗
February 18, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
January 30, 2026
Via
Chartmill
Aprea Therapeutics: Q4 Earnings Insights
↗
March 26, 2024
Via
Benzinga
Check out the stocks that are attracting the most attention and driving market activity.
↗
January 30, 2026
Via
Chartmill
In today's session, these stocks are experiencing unusual volume.
↗
January 30, 2026
Via
Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session.
↗
January 30, 2026
Via
Chartmill
What's going on in today's after hours session
↗
January 29, 2026
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
September 17, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
July 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 31, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 15, 2024
Via
Benzinga
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 12, 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
↗
May 14, 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 04, 2024
Via
Benzinga
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
↗
March 26, 2024
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
↗
March 11, 2024
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 11, 2024
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
↗
October 30, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
↗
September 25, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
↗
September 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 18, 2023
Via
Benzinga
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
↗
June 09, 2023
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 07, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
April 03, 2023
On Monday, 76 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
↗
March 10, 2023
Via
Benzinga
Why Aprea Therapeutics Shares Hit A New 52-Week Low Today
↗
February 23, 2023
Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 23, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
